Trials / Terminated
TerminatedNCT02684617
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | pembrolizumab | 200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days. |
| DRUG | dinaciclib | dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days. |
Timeline
- Start date
- 2016-03-29
- Primary completion
- 2020-04-06
- Completion
- 2020-04-06
- First posted
- 2016-02-18
- Last updated
- 2021-03-01
- Results posted
- 2021-03-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02684617. Inclusion in this directory is not an endorsement.